Antiseizure Properties of Histamine H3 Receptor Antagonists Belonging 3,4-Dihydroquinolin-2(1H)-Ones
Open Access
Abstract
H3R is becoming an attractive and promising target for epilepsy treatment as well as the discovery of antiepileptics. In this work, a series of 6-aminoalkoxy-3,4-dihydroquinolin-2(1H)-ones was prepared to screen their H3R antagonistic activities and antiseizure effects. The majority of the target compounds displayed a potent H3R antagonistic activity. Among them, compounds 2a, 2c, 2h, and 4a showed submicromolar H3R antagonistic activity with an IC50 of 0.52, 0.47, 0.12, and 0.37 μM, respectively. The maximal electroshock seizure (MES) model screened out three compounds (2h, 4a, and 4b) with antiseizure activity. Meanwhile, the pentylenetetrazole (PTZ)-induced seizure test gave a result that no compound can resist the seizures induced by PTZ. Additionally, the anti-MES action of compound 4a fully vanished when it was administrated combined with an H3R agonist (RAMH). These results showed that the antiseizure role of compound 4a might be achieved by antagonizing the H3R receptor. The molecular docking of 2h, 4a, and PIT with the H3R protein predicted their possible binding patterns and gave a presentation that 2h, 4a, and PIT had a similar binding model with H3R.Keywords
Funding Information
- National Natural Science Foundation of China (22167017)
This publication has 33 references indexed in Scilit:
- Anticonvulsive effect of nonimidazole histamine H3 receptor antagonistsBehavioural Pharmacology, 2014
- Design, synthesis and evaluation of the antidepressant and anticonvulsant activities of triazole-containing quinolinonesEuropean Journal of Medicinal Chemistry, 2014
- The CRE luc Bioluminescence Transgenic Mouse Model for Detecting Ligand Activation of GPCRsSLAS Discovery, 2014
- Efficacy of the histamine 3 receptor (H3R) antagonist pitolisant (formerly known as tiprolisant; BF2.649) in epilepsy: Dose-dependent effects in the human photosensitivity modelEpilepsy & Behavior, 2013
- Histamine H3receptor antagonists in relation to epilepsy and neurodegeneration: a systemic consideration of recent progress and perspectivesBritish Journal of Pharmacology, 2012
- Correction: Identification and Characterization of ZEL-H16 as a Novel Agonist of the Histamine H3ReceptorPLOS ONE, 2012
- Identification and Characterization of ZEL-H16 as a Novel Agonist of the Histamine H3 ReceptorPLOS ONE, 2012
- Structure of the human histamine H1 receptor complex with doxepinNature, 2011
- The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neuronsEuropean Journal of Pharmacology, 2007
- Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptorNature, 1983